E3330
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406611

CAS#: 136164-66-4

Description: E3330 is a potent and selective inhibitor of AP endonuclease 1 redox domain.E3330 significantly reduces the growth of human pancreatic cancer cells in vitro and inhibits pancreatic cancer cell migration. E3330 blocks tnf-α-induced activation of IL-8 production in liver cancer cell lines. E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis.


Price and Availability

Size
Price

10mg
USD 250
100mg
USD 950
1g
USD 3950
Size
Price

25mg
USD 450
200mg
USD 1450
2g
USD 4950
Size
Price

50mg
USD 650
500mg
USD 2650
5g
Ask price

E3330, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406611
Name: E3330
CAS#: 136164-66-4
Chemical Formula: C21H30O6
Exact Mass: 378.20424
Molecular Weight: 378.46
Elemental Analysis: C, 66.65; H, 7.99; O, 25.37


Synonym: E3330; E-3330; E 3330.

IUPAC/Chemical Name: (E)-2-((4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylene)undecanoic acid

InChi Key: AALSSIXXBDPENJ-FYWRMAATSA-N

InChi Code: InChI=1S/C21H30O6/c1-5-6-7-8-9-10-11-12-15(21(24)25)13-16-14(2)17(22)19(26-3)20(27-4)18(16)23/h13H,5-12H2,1-4H3,(H,24,25)/b15-13+

SMILES Code: CCCCCCCCC/C(C(O)=O)=C\C1=C(C)C(C(OC)=C(OC)C1=O)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
 
 
 


References

1: Cesaratto L, Codarin E, Vascotto C, Leonardi A, Kelley MR, Tiribelli C, Tell G. Specific inhibition of the redox activity of ape1/ref-1 by e3330 blocks tnf-α-induced activation of IL-8 production in liver cancer cell lines. PLoS One. 2013 Aug 15;8(8):e70909. doi: 10.1371/journal.pone.0070909. eCollection 2013. PubMed PMID: 23967134; PubMed Central PMCID: PMC3744539.

2: Kelley MR, Luo M, Reed A, Su D, Delaplane S, Borch RF, Nyland RL 2nd, Gross ML, Georgiadis MM. Functional analysis of novel analogues of E3330 that block the redox signaling activity of the multifunctional AP endonuclease/redox signaling enzyme APE1/Ref-1. Antioxid Redox Signal. 2011 Apr 15;14(8):1387-401. doi: 10.1089/ars.2010.3410. Epub 2011 Jan 4. PubMed PMID: 20874257; PubMed Central PMCID: PMC3061197.

3: Zou GM, Karikari C, Kabe Y, Handa H, Anders RA, Maitra A. The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis. J Cell Physiol. 2009 Apr;219(1):209-18. doi: 10.1002/jcp.21666. PubMed PMID: 19097035.

4: Zou GM, Maitra A. Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration. Mol Cancer Ther. 2008 Jul;7(7):2012-21. doi: 10.1158/1535-7163.MCT-08-0113. PubMed PMID: 18645011; PubMed Central PMCID: PMC3569736.

5: Saitou Y, Shiraki K, Yamanaka T, Miyashita K, Inoue T, Yamanaka Y, Yamaguchi Y, Enokimura N, Yamamoto N, Itou K, Sugimoto K, Nakano T. Augmentation of tumor necrosis factor family-induced apoptosis by E3330 in human hepatocellular carcinoma cell lines via inhibition of NF kappa B. World J Gastroenterol. 2005 Oct 28;11(40):6258-61. PubMed PMID: 16419152.

6: Hiramoto M, Shimizu N, Sugimoto K, Tang J, Kawakami Y, Ito M, Aizawa S, Tanaka H, Makino I, Handa H. Nuclear targeted suppression of NF-kappa B activity by the novel quinone derivative E3330. J Immunol. 1998 Jan 15;160(2):810-9. PubMed PMID: 9551916.

7: Uetsuka K, Suzuki M, Kai C, Goto N. Protective effects of a novel quinone derivative, E3330, on mouse hepatitis virus (MHV)-induced chronic hepatitis in athymic nude mice. Exp Anim. 1997 Jul;46(3):219-23. PubMed PMID: 9250483.

8: Goto M, Yamada K, Katayama K, Tanaka I. Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on activation of nuclear factor-kappa B. Mol Pharmacol. 1996 May;49(5):860-73. PubMed PMID: 8622636.

9: Tanaka H, Makino Y, Hiramoto M, Handa H, Makino I. Potentiation of glucocorticoid-mediated gene expression by the novel benzoquinone derivative (2E)-3-[5-(2,3-dimethoxy-o-methyl-1, 4-benzoquinoyl)]-2-nonyl-2-propenoic acid (E3330). Eur J Pharmacol. 1995 Oct 15;291(2):121-7. PubMed PMID: 8566161.

10: Wasaki S, Sakaida I, Nagatomi A, Matsumura Y, Yasunaga M, Okita K. The effect of E3330 on active oxygen generation by isolated hepatic macrophages in rats. J Gastroenterol. 1995 Apr;30(2):273-4. PubMed PMID: 7773361.